Mark E. McDonnell
Research Subjects
Mark E. McDonnell has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
Lois Tolvinski
The Wistar Institute, 3601 Spruce Street, Philadelphia, Pennsylvania 19104, United States
2 shared publicationsSamantha S. Soldan
The Wistar Institute, 3601 Spruce Street, Philadelphia, Pennsylvania 19104, United States
2 shared publicationsVenkata Velvadapu
Fox Chase Therapeutics Discovery, Inc., 3805 Old Easton Road, Doylestown, Pennsylvania 18902, United States
2 shared publicationsYan Zhang
Fox Chase Therapeutics Discovery, Inc., 3805 Old Easton Road, Doylestown, Pennsylvania 18902, United States
2 shared publicationsA. Pieter J. van Den Heuvel
Vironika LLC, 3624 Market Street, Ste 5E, Philadelphia, PA 19104, USA
1 shared publicationAlice Bull
Department of Chemistry, Department of Biology, and Drug Discovery Support, Novartis Horsham Research Centre, Wimblehurst Road, Horsham, West Sussex RH12 5AB, U.K., and Ciba Central Research Laboratories, Hulley Road, Macclesfield, Cheshire SK10 2NX, U.K.
1 shared publication
Latest Publications
- 11 June 2026
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 17 (7) , 1517-1523
Design and Optimization of Benzoic Acid Inhibitors Targeting the EBNA1 DNA-Binding Interface
Epstein–Barr nuclear antigen 1 (EBNA1) is an essential viral DNA-binding protein required for maintenance of Epstein–Barr virus (EBV) episomes and is expressed in all EBV-associated malignancies, making it an attractive therapeutic target. Using fragment-based screening and X-ray crystallography, we identified a 2,3-disubstituted benzoic acid scaffold that binds at the EBNA1 DNA-binding interface. Structure-guided optimization revealed that the carboxylic acid pharmacophore engages Asn519 and Thr590, while electron-rich heterocycles are positioned between Lys477 and Lys586, forming a cation−π–cation “lysine sandwich” that drives potency. Iterative medicinal chemistry improved binding affinity and physicochemical stability, leading to compound 35 (VK-2019), a submicromolar EBNA1 to DNA binding inhibitor. Compound 35 demonstrated favorable drug-like properties and robust antitumor efficacy in EBV-positive xenograft models and has advanced to clinical evaluation. These studies define the structural determinants of EBNA1 inhibition and establish a framework for targeting viral genome-maintenance proteins with small molecules.
- 11 June 2026
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 17 (7) , 1517-1523
Design and Optimization of Benzoic Acid Inhibitors Targeting the EBNA1 DNA-Binding Interface
Epstein–Barr nuclear antigen 1 (EBNA1) is an essential viral DNA-binding protein required for maintenance of Epstein–Barr virus (EBV) episomes and is expressed in all EBV-associated malignancies, making it an attractive therapeutic target. Using fragment-based screening and X-ray crystallography, we identified a 2,3-disubstituted benzoic acid scaffold that binds at the EBNA1 DNA-binding interface. Structure-guided optimization revealed that the carboxylic acid pharmacophore engages Asn519 and Thr590, while electron-rich heterocycles are positioned between Lys477 and Lys586, forming a cation−π–cation “lysine sandwich” that drives potency. Iterative medicinal chemistry improved binding affinity and physicochemical stability, leading to compound 35 (VK-2019), a submicromolar EBNA1 to DNA binding inhibitor. Compound 35 demonstrated favorable drug-like properties and robust antitumor efficacy in EBV-positive xenograft models and has advanced to clinical evaluation. These studies define the structural determinants of EBNA1 inhibition and establish a framework for targeting viral genome-maintenance proteins with small molecules.
- 18 January 2023
- Published by Elsevier in Tetrahedron Letters
- Vol. 117
Efficient syntheses of KLS-13019 using palladium mediated cross couplings
- 18 January 2023
- Published by Elsevier in Tetrahedron Letters
- Vol. 117
Efficient syntheses of KLS-13019 using palladium mediated cross couplings
- 6 March 2019
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 11 (482)
Structure-based design of small-molecule inhibitors of EBNA1 DNA binding blocks Epstein-Barr virus latent infection and tumor growth
EBNA1 inhibitors developed by fragment-based drug design block EBNA1 DNA binding and EBV-dependent tumor cell growth in vivo.
- 6 March 2019
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 11 (482)
Structure-based design of small-molecule inhibitors of EBNA1 DNA binding blocks Epstein-Barr virus latent infection and tumor growth
EBNA1 inhibitors developed by fragment-based drug design block EBNA1 DNA binding and EBV-dependent tumor cell growth in vivo.
- 27 November 2014
- Published by Springer Nature
- p. 95-107
Folding
- 8 October 1999
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 42 (22) , 4584-4603
Design and Synthesis of Thrombin Inhibitors: Analogues of MD-805 with Reduced Stereogenicity and Improved Potency
Mitsubishi's MD-805, a potent and selective inhibitor of thrombin which contains four stereogenic centers, has been the starting point for an optimization program. A systematic synthetic study resulted in thrombin inhibitors achiral at P2 and P3 but with a 10-fold increase in potency over the original lead. A number of 4-substituted piperidines were synthesized and examined as replacements for 2-carboxy-4-methylpiperidine at P2; 4-fluoroethylpiperidine (FEP) among others provided inhibitors (e.g. 45g) of increased potency. An enantioselective route was developed to 3(R)-methyl-1,2,3,4-tetrahydroquinolinesulfonyl chloride. Inhibitors containing this enantiomerically pure P3 (42d) had similar potency to the racemic material and provided support, with modeling studies, for the preparation of the gem 3,3-disubstituted compounds. A series of inhibitors containing the novel 3,3-dimethyl-1,2,3,4-tetrahydroquinolinesulfonyl (DMTHQS) P3 (Table 5) were synthesized and showed a similar activity profile as the monomethyl series. The combination of P3-DMTHQS, P2-FEP, and P1-arginine (45 g ) had a Ki of 6 nM (MD-805 Ki = 85 nM). In animal models of both venous and arterial thrombosis, one inhibitor (42e) was shown to produce a dose-dependent inhibition of thrombus formation that in some situations was superior to that of MD-805.
- 8 October 1999
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 42 (22) , 4584-4603
Design and Synthesis of Thrombin Inhibitors: Analogues of MD-805 with Reduced Stereogenicity and Improved Potency
Mitsubishi's MD-805, a potent and selective inhibitor of thrombin which contains four stereogenic centers, has been the starting point for an optimization program. A systematic synthetic study resulted in thrombin inhibitors achiral at P2 and P3 but with a 10-fold increase in potency over the original lead. A number of 4-substituted piperidines were synthesized and examined as replacements for 2-carboxy-4-methylpiperidine at P2; 4-fluoroethylpiperidine (FEP) among others provided inhibitors (e.g. 45g) of increased potency. An enantioselective route was developed to 3(R)-methyl-1,2,3,4-tetrahydroquinolinesulfonyl chloride. Inhibitors containing this enantiomerically pure P3 (42d) had similar potency to the racemic material and provided support, with modeling studies, for the preparation of the gem 3,3-disubstituted compounds. A series of inhibitors containing the novel 3,3-dimethyl-1,2,3,4-tetrahydroquinolinesulfonyl (DMTHQS) P3 (Table 5) were synthesized and showed a similar activity profile as the monomethyl series. The combination of P3-DMTHQS, P2-FEP, and P1-arginine (45 g ) had a Ki of 6 nM (MD-805 Ki = 85 nM). In animal models of both venous and arterial thrombosis, one inhibitor (42e) was shown to produce a dose-dependent inhibition of thrombus formation that in some situations was superior to that of MD-805.